Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

TNYA Tenaya Therapeutics

Watchlist
5.450
-0.180-3.20%
Close 07/01 16:00 ET
5.45000.00%
Post Mkt Price 07/01 16:01 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
5.840
Open
5.700
Turnover
312.33K
Low
5.220
Pre Close
5.630
Volume
57.01K
Market Cap
225.14M
P/E(TTM)
Loss
52wk High
32.000
Shares
41.31M
P/E(Static)
Loss
52wk Low
4.736
Float Cap
103.59M
Bid/Ask %
-33.33%
Historical High
32.000
Shs Float
19.01M
Volume Ratio
0.21
Historical Low
4.736
Dividend TTM
--
Div Yield TTM
--
P/B
0.90
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.30%
Amplitude
11.01%
Avg Price
5.478
Lot Size
1
Float Cap
103.59M
Bid/Ask %
-33.33%
Historical High
32.000
Shs Float
19.01M
Volume Ratio
0.21
Historical Low
4.736
Dividend TTM
--
P/B
0.90
Dividend LFY
--
Turnover Ratio
0.30%
Amplitude
11.01%
Avg Price
5.478
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
CEO: Ali M.B.A., Faraz
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top